190 related articles for article (PubMed ID: 9379009)
1. Altered peptide ligands trigger perforin- rather than Fas-dependent cell lysis.
Bachmann MF; Ohteki T; Faienza KM; Zakarian A; Kägi D; Speiser DE; Ohashi PS
J Immunol; 1997 Nov; 159(9):4165-70. PubMed ID: 9379009
[TBL] [Abstract][Full Text] [Related]
2. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
[TBL] [Abstract][Full Text] [Related]
3. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways.
Lowin B; Hahne M; Mattmann C; Tschopp J
Nature; 1994 Aug; 370(6491):650-2. PubMed ID: 7520535
[TBL] [Abstract][Full Text] [Related]
4. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.
Benihoud K; Bonardelle D; Bobé P; Kiger N
Eur J Immunol; 1997 Feb; 27(2):415-20. PubMed ID: 9045912
[TBL] [Abstract][Full Text] [Related]
5. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism.
Williams NS; Engelhard VH
J Immunol; 1996 Jan; 156(1):153-9. PubMed ID: 8598456
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
[TBL] [Abstract][Full Text] [Related]
7. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements.
Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y
J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121
[TBL] [Abstract][Full Text] [Related]
8. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K
J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902
[TBL] [Abstract][Full Text] [Related]
9. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production.
Kessler B; Hudrisier D; Schroeter M; Tschopp J; Cerottini JC; Luescher IF
J Immunol; 1998 Dec; 161(12):6939-46. PubMed ID: 9862728
[TBL] [Abstract][Full Text] [Related]
10. Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms.
Lewinsohn DM; Bement TT; Xu J; Lynch DH; Grabstein KH; Reed SG; Alderson MR
J Immunol; 1998 Mar; 160(5):2374-9. PubMed ID: 9498779
[TBL] [Abstract][Full Text] [Related]
11. The role of the Fas lytic pathway in a perforin-less CTL hybridoma.
Walsh CM; Glass AA; Chiu V; Clark WR
J Immunol; 1994 Sep; 153(6):2506-14. PubMed ID: 7521365
[TBL] [Abstract][Full Text] [Related]
12. Leukocyte function-associated antigen-1-dependent lysis of Fas+ (CD95+/Apo-1+) innocent bystanders by antigen-specific CD8+ CTL.
Kojima H; Eshima K; Takayama H; Sitkovsky MV
J Immunol; 1997 Sep; 159(6):2728-34. PubMed ID: 9300693
[TBL] [Abstract][Full Text] [Related]
13. IL-1 beta convertase (ICE) does not play a requisite role in apoptosis induced in T lymphoblasts by Fas-dependent or Fas-independent CTL effector mechanisms.
Smith DJ; McGuire MJ; Tocci MJ; Thiele DL
J Immunol; 1997 Jan; 158(1):163-70. PubMed ID: 8977187
[TBL] [Abstract][Full Text] [Related]
14. Veto activity of activated bone marrow does not require perforin and Fas ligand.
Chrobak P; Gress RE
Cell Immunol; 2001 Mar; 208(2):80-7. PubMed ID: 11333140
[TBL] [Abstract][Full Text] [Related]
15. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.
Ando K; Hiroishi K; Kaneko T; Moriyama T; Muto Y; Kayagaki N; Yagita H; Okumura K; Imawari M
J Immunol; 1997 Jun; 158(11):5283-91. PubMed ID: 9164947
[TBL] [Abstract][Full Text] [Related]
16. Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis.
Vergelli M; Hemmer B; Muraro PA; Tranquill L; Biddison WE; Sarin A; McFarland HF; Martin R
J Immunol; 1997 Mar; 158(6):2756-61. PubMed ID: 9058810
[TBL] [Abstract][Full Text] [Related]
17. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2.
Schröter M; Lowin B; Borner C; Tschopp J
Eur J Immunol; 1995 Dec; 25(12):3509-13. PubMed ID: 8566045
[TBL] [Abstract][Full Text] [Related]
19. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
20. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
